213 related articles for article (PubMed ID: 31452933)
1. Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma.
Jafarnejad M; Sové RJ; Danilova L; Mirando AC; Zhang Y; Yarchoan M; Tran PT; Pandey NB; Fertig EJ; Popel AS
NPJ Syst Biol Appl; 2019; 5():29. PubMed ID: 31452933
[TBL] [Abstract][Full Text] [Related]
2. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
3. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
4. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
6. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
[TBL] [Abstract][Full Text] [Related]
7. Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.
Xiang QF; Zhan MX; Li Y; Liang H; Hu C; Huang YM; Xiao J; He X; Xin YJ; Chen MS; Lu LG
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):83-89. PubMed ID: 30663411
[TBL] [Abstract][Full Text] [Related]
8. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53.
Liu WT; Jing YY; Yu GF; Chen H; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
Cell Cycle; 2016; 15(7):886-94. PubMed ID: 27077227
[TBL] [Abstract][Full Text] [Related]
9. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
[TBL] [Abstract][Full Text] [Related]
10. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
11. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
12. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
13. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Lee HJ; Eun JY; Kim HG; Yoon SS; Lee DS; Kim JH; Kim JR
Clin Exp Metastasis; 2008; 25(1):89-96. PubMed ID: 17992475
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
Liu Y; Tan J; Ou S; Chen J; Chen L
Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
[TBL] [Abstract][Full Text] [Related]
15. The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
Shintani T; Kusuhara Y; Daizumoto K; Dondoo TO; Yamamoto H; Mori H; Fukawa T; Nakatsuji H; Fukumori T; Takahashi M; Kanayama H
Urology; 2017 Mar; 101():169.e7-169.e13. PubMed ID: 28013036
[TBL] [Abstract][Full Text] [Related]
16. LINC00240 sponges miR-4465 to promote proliferation, migration, and invasion of hepatocellular carcinoma cells via HGF/c-MET signaling pathway.
Bu WJ; Fang Z; Li WL; Wang X; Dong MJ; Tao QY; Zhang L; Xu YQ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10452-10461. PubMed ID: 33155201
[TBL] [Abstract][Full Text] [Related]
17. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
18. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
19. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2.
Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS
Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.
Gao F; Deng G; Liu W; Zhou K; Li M
Oncol Rep; 2017 Feb; 37(2):1203-1211. PubMed ID: 28075467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]